Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2023-186284

Published: 2023

Journal Articles

Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation

Michael Fradley, Marie-Hélène Lafeuille, Bruno Emond, Samuel Crawford, Naijun Chen, Raisa Volodarsky, Jacqueline Nielsen, Bhavini Patel Srivastava

Blood (2022) 140 (Supplement 1): 10983–10984.

https://doi.org/10.1182/blood-2022-162797

Published: 2022

Journal Articles

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frédéric Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda Wu, Zaina P. Qureshi, Moshe Yair Levy

Blood (2022) 140 (Supplement 1): 1931–1933.

https://doi.org/10.1182/blood-2022-163387

Published: 2022

Journal Articles

Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Anna Narezkina, Xiaoxiao Lu, Bruno Emond, Aurélie Côté-Sergent, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang

Blood (2021) 138 (Supplement 1): 4112.

https://doi.org/10.1182/blood-2021-148640

Published: 2021

Journal Articles

Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Ibrutinib

Swetha Challagulla, Bruno Emond, Raisa R. Volodarsky, Alex Young, Ameur Manceur, Sudeep Karve

Blood (2021) 138 (Supplement 1): 4016.

https://doi.org/10.1182/blood-2021-145117

Published: 2021

Journal Articles

Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Kerry Rogers, Bruno Emond, Aurélie Côté-Sergent, Frédéric Kinkead, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang

Blood (2021) 138 (Supplement 1): 4030.

https://doi.org/10.1182/blood-2021-148575

Published: 2021

Journal Articles

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Song Wang, PhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA, Murali Sundaram, MBA, PhD, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 2306.

https://doi.org/10.1182/blood-2018-99-116473

Published: 2018

Journal Articles

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Marie-Hélène Lafeuille, MA, Murali Sundaram, MBA, PhD, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 4714.

https://doi.org/10.1182/blood.V130.Suppl_1.4714.4714

Published: 2017

Journal Articles

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Murali Sundaram, MBA, PhD, Marie-Hélène Lafeuille, MA, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 5600.

https://doi.org/10.1182/blood.V130.Suppl_1.5600.5600

Published: 2017

NARROW

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Ibrutinib

Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only